Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

NCT06082934 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia

Interventions

DRUG: Olverembatinib plus venetoclax and dexamethasone

Sponsor

Xijing Hospital